Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Interstitial Lung Disease (ILD) Clear all
Not listed No phase listed Observational

Patient-Reported Outcome Study of Project ECHO for ILD

NCT05450276
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 6, 2026, 2:00 PM EDT
Withdrawn No phase listed Observational

Identification of Novel Markers of Human Lung Disease

NCT02369575
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
novel biomarkers of lung disease
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 6, 2026, 2:00 PM EDT
Enrolling by invitation Not applicable Interventional

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

NCT07512687
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Hypoxemia
Interventions
Portable Oxygen Concentrator, Portable compressed oxygen D-tanks, No ambulatory oxygen therapy
Device · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Not yet recruiting No phase listed Observational

Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)

NCT07217093
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease
Interventions
Not listed
Lead sponsor
St. Lawrence Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Potsdam, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

NCT04071769
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

NCT03092102
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC585
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 6, 2026, 2:00 PM EDT
Completed No phase listed Observational

Quality of Life in IPF - Patient and Physician Perceptions

NCT04148157
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Early Phase 1 Interventional

Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

NCT05976217
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Venetoclax
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Completed No phase listed Observational

Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

NCT01289717
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Completed No phase listed Observational Results available

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 6, 2026, 2:00 PM EDT
Recruiting No phase listed Observational

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT03004326
View directory record Official record
Conditions
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
Interventions
Not listed
Lead sponsor
Peter Merkel
Other
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Not applicable Interventional

Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)

NCT01972685
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Cryobiopsy biopsy, Transbronchial Biopsy, VATS biopsy
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 6, 2026, 2:00 PM EDT
Completed No phase listed Observational Results available

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

NCT05022784
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Not applicable Interventional Results available

Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT01118221
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
pulmonary rehabilitation
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Results available

Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

NCT01169038
View directory record Official record
Conditions
Pulmonary Sarcoidosis, Lung Function
Interventions
levaquin; ethambutol; rifampin and azithromycin.
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 6, 2026, 2:00 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis

NCT02187393
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Healthy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 6, 2026, 2:00 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

NCT01776398
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 6, 2026, 2:00 PM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01759511
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 6, 2026, 2:00 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 6, 2026, 2:00 PM EDT
Active, not recruiting No phase listed Observational

PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort

NCT02407431
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Recruiting No phase listed Observational

Explanted Lung Tissues With Pulmonary Fibrosis

NCT00515567
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 6, 2026, 2:00 PM EDT
Withdrawn No phase listed Observational

Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

NCT00212511
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 6, 2026, 2:00 PM EDT
Completed Phase 2 Interventional Results available

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

NCT03220035
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions
Laboratory Biomarker Analysis, Vemurafenib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 6, 2026, 2:00 PM EDT